MetaCap

NRX Pharmaceuticals (NRXP) vs vTv Therapeutics (VTVT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.

Summary

vTv Therapeutics (VTVT) has outperformed NRX Pharmaceuticals (NRXP) over the past year, gaining 36.0% versus a loss of 19.3%. Over five years, VTVT leads with a -48.8% price change compared with -97.2% for NRXP. NRX Pharmaceuticals is the larger company by market cap ($123.2 million vs $121.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NRXP-19.27%VTVT+35.99%
+100%+20%-60%
Oct 8, 20251 yearOct 8, 2026
NRXP-95.84%VTVT-53.29%
+55%-25%-106%
Oct 4, 20215 yearsOct 5, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NRXP versus VTVT key metrics
MetricNRXPVTVT
Share price$2.85$30.80
Market cap$123.18M$121.78M
1-day change-1.56%+2.39%
YTD return+6.64%-24.78%
1-year return-19.27%+35.99%
5-year return-97.18%-48.84%
EPS (TTM)$-0.58$-0.72
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
52-week high$5.06$44.00
52-week low$1.62$19.50
Distance from 52-week high-43.72%-30.00%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+1253.25%+77.63%
Average volume865.49K68.13K
Shares outstanding43.30M3.95M
Employees2926
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • VTVT has outperformed NRXP by 55.3 percentage points over the past year.

About NRX Pharmaceuticals

NRXP stock →

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments.

Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees

About vTv Therapeutics

VTVT stock →

vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes.

Health Care · Biotechnology: Pharmaceutical Preparations · 26 employees

NRXP vs VTVT FAQ

Which is bigger, NRX Pharmaceuticals or vTv Therapeutics?

NRX Pharmaceuticals (NRXP) is larger, with a market capitalization of $123.18M compared with $121.78M for vTv Therapeutics (VTVT).

Which stock has performed better over the past year, NRXP or VTVT?

VTVT returned +35.99% over the past 12 months, compared with -19.27% for NRXP (price return, excluding dividends). Past performance does not predict future results.

Are NRX Pharmaceuticals and vTv Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons